This inventor holds 1 USPTO granted patent. Top assignee: Peking University. Active years: 2012.
Company Filing History:
Years Active: 2012
Title: Yexia Cheng: Innovator in Ovarian Cancer Research
Introduction
Yexia Cheng is a prominent inventor based in Beijing, China. He has made significant contributions to the field of cancer research, particularly in the development of innovative treatments for ovarian cancer. His work focuses on the use of T-cell epitope peptides to enhance the effectiveness of anti-cancer therapies.
Latest Patents
Yexia Cheng holds a patent for "T cell epitope peptides of ovarian cancer anti-idiotypic antibody 6B11 and use thereof." This invention provides two T-cell epitope peptides derived from the anti-idiotype antibody 6B11, specifically designed to target ovarian cancer cells. The sequences of these peptides are detailed in SEQ ID NO:3 or 6. The patent outlines the potential use of these peptides in the manufacture of vaccines aimed at treating and preventing ovarian cancer. Notably, these T-cell epitope peptides have the capability to specifically kill OC166-9 positive ovarian cancer cells, showcasing their promise in cancer therapy.
Career Highlights
Yexia Cheng is affiliated with Peking University, where he conducts his research and development activities. His work has garnered attention for its innovative approach to cancer treatment, particularly through the use of targeted therapies that leverage the immune system's capabilities.
Collaborations
Yexia Cheng collaborates with esteemed colleagues such as Wei Li and Heng Cui. Their combined expertise contributes to advancing research in the field of oncology and the development of effective cancer treatments.
Conclusion
Yexia Cheng's contributions to ovarian cancer research through his patented innovations highlight the importance of targeted therapies in modern medicine. His work not only advances scientific knowledge but also holds the potential to improve patient outcomes in the fight against cancer.